Signaturefd LLC Purchases 72 Shares of ResMed Inc. (NYSE:RMD)

Signaturefd LLC raised its position in shares of ResMed Inc. (NYSE:RMD) by 1.7% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,211 shares of the medical equipment provider’s stock after purchasing an additional 72 shares during the quarter. Signaturefd LLC’s holdings in ResMed were worth $1,028,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. UMB Bank n.a. increased its position in shares of ResMed by 1.9% during the third quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider’s stock valued at $602,000 after acquiring an additional 47 shares in the last quarter. Dorsey & Whitney Trust CO LLC increased its holdings in shares of ResMed by 3.7% in the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 1,473 shares of the medical equipment provider’s stock worth $292,000 after purchasing an additional 52 shares in the last quarter. QRG Capital Management Inc. increased its holdings in shares of ResMed by 4.5% in the 2nd quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider’s stock worth $247,000 after purchasing an additional 56 shares in the last quarter. Inspire Advisors LLC raised its stake in shares of ResMed by 1.9% in the second quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider’s stock worth $586,000 after purchasing an additional 56 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. lifted its holdings in shares of ResMed by 1.9% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 3,188 shares of the medical equipment provider’s stock valued at $631,000 after purchasing an additional 60 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on RMD. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Royal Bank of Canada boosted their price objective on shares of ResMed from $206.00 to $224.00 and gave the company a “sector perform” rating in a report on Tuesday, October 1st. Needham & Company LLC restated a “hold” rating on shares of ResMed in a report on Tuesday, October 1st. Wolfe Research reaffirmed an “underperform” rating and issued a $180.00 target price on shares of ResMed in a research report on Wednesday, September 18th. Finally, Bank of America increased their price target on ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $218.18.

Insiders Place Their Bets

In other news, CFO Brett Sandercock sold 1,000 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $212.16, for a total value of $212,160.00. Following the transaction, the chief financial officer now directly owns 89,056 shares in the company, valued at $18,894,120.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Kaushik Ghoshal sold 4,260 shares of ResMed stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $238.48, for a total transaction of $1,015,924.80. Following the sale, the insider now owns 21,788 shares in the company, valued at $5,196,002.24. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Brett Sandercock sold 1,000 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $212.16, for a total transaction of $212,160.00. Following the transaction, the chief financial officer now owns 89,056 shares of the company’s stock, valued at approximately $18,894,120.96. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 123,874 shares of company stock worth $28,151,142. Corporate insiders own 1.21% of the company’s stock.

ResMed Stock Down 1.1 %

NYSE RMD opened at $237.40 on Thursday. The stock’s 50-day moving average price is $239.99 and its 200-day moving average price is $217.20. The company has a market capitalization of $34.88 billion, a P/E ratio of 36.47, a price-to-earnings-growth ratio of 2.15 and a beta of 0.69. The company has a quick ratio of 1.69, a current ratio of 2.59 and a debt-to-equity ratio of 0.14. ResMed Inc. has a 52 week low of $132.24 and a 52 week high of $255.18.

ResMed (NYSE:RMD) last released its earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.05. The company had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.22 billion. ResMed had a net margin of 21.79% and a return on equity of 25.00%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.60 EPS. On average, equities research analysts predict that ResMed Inc. will post 9.08 earnings per share for the current year.

ResMed Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 19th. Investors of record on Thursday, August 15th were issued a $0.53 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $2.12 annualized dividend and a yield of 0.89%. This is an increase from ResMed’s previous quarterly dividend of $0.48. ResMed’s dividend payout ratio is currently 32.57%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.